 |
This conference will be simultaneously translated 此会议将会有中英同声翻译
"The global vaccines market is expected to reach US$56.7 billion
by 2017 with double-digit growth annually."
Of all major vaccines-producing countries, development is highly anticipated from China, fuelled by WHO's March announcement enabling manufacturers to apply for pre-qualifi cations and subsequent eligibility under the UN procurement program. This opens the door to a signifi cant market, driving China vaccines manufacturers to upgrade production to meet stricter quality requirements. Further collaboration with international organizations is predicted, in efforts to strengthen vaccines development.
IBC's 4th Vaccines China 2012 is timely and has been researched with the industry to provide the most comprehensive event focused on vaccines development through to manufacturing. Good manufacturing practices and strategies will be reviewed, alongside potential block-buster technologies and R&D projects. This conference is co-located with the 7th annual China Pharmaceutical R&D Summit and 3rd annual Biosimilars Asia conference to maximize cross-learning, partnering and networking opportunities with biopharma and related industries.
Featuring Presentations from Leading Experts
| Government Institutions |
 |
Dr. Masato Tashiro
MD. PhD, Director, Influenza Virus Research Center, National Institute of Infectious Diseases, Japan |
 |
Dr. Pele Chong
Director and Distinguished Investigator, Vaccines Research and Development Center, National Health Research Institute, Taiwan |
 |
Prof. Sudhanshu Vrati
PhD, FASc, FNASc, Dean, Translational Health Science and Technology Institute & Head, Vaccine and Infectious Disease Research Centre & Principal Scientist, National Institute of Immunology, India |
 |
Jun Wu
Trainer, State Food and Drug Administration Institute of Executive Development, China |
| International Experts |
 |
Drew Natenshon，Head - China Research Strategy and Operations， Novartis Vaccines & Diagnostics， China |
 |
Dr. Alain Bouckenooghe
MD, MPH , Clinical R&D and Medical Affairs, Associate VP, Regional Head Asia/Pacific, Sanofi Pasteur, Singapore |
 |
Prof. Nikolai Petrovsky
Director of Endocrinology, Flinders Medical Centre & Research Director, Vaxine Pty Ltd, Australia |
 |
Dr. De-chu C. Tang
Ph.D, Founder, VP & CTO, Vaxin Inc, USA |
|
| China Industry Leaders |
 |
Dr. Aihua Zhang
Professor and Deputy Director of R&D Department, China National Biotec Group(CNBG), China National Pharmaceutical Group Corp.(Sinopharm), China |
 |
Jin Yulan
President, Changchun Institute of Biological Products, China |
 |
Dr. Li Shi
Ph.D., CEO, Shanghai Zerun Biotechnology, Wison Group, China |
 |
Dr. Gao Qiang
Director of R&D, Sinovac Biotech Co. Ltd, China |
 |
Dr. Bin Wang
Ph.D, Professor, Key Laboratory of Medical Molecular Virology of MOH and MOE, Fudan University Shanghai Medical College, China |
 |
Dr. Jean-Denis Shu
MD MBA, Medical Director, Sanofi Pasteur, China |
 |
Dr. Tang Haiwen
MD. Ph. D., Director, Clinical Research and Medical Affairs, GSK Biologicals China/ Hong Kong, China |
|
| |
|
 |
ABOUT DRUG DISCOVERY WEEK |
|
| |
As world attention continues to shift towards Asia, increasing and ongoing investment into the pharmaceutical industry has come to fruition, matched by rapidly growing demand from the region. Funded by mostly private and emerging government supported initiatives, China is leading efforts as the future source of innovation and producer of quality medicines. Whether in new drug and vaccines discovery and development or in biosimilars, the time is ripe in China! |
|
| |
|
|
5 TOP REASONS TO ATTEND |
|
| |
- Gain insights into quality and compliance strategies by international and local vaccines manufacturers.
- Identify prospective research projects and technologies for strategic collaborations.
- Evaluate opportunities currently present in the vaccines market and its relevant risks.
- Benchmark your manufacturing practices and policies against the leading players in the industry.
- Assess future trends and the next generation of vaccines
|
|
| |
|
|
WHAT'S NEW IN 2012? |
|
| |
- SHOWCASE latest research findings and new technologies in the vaccines development
- NEW focus on quality and compliance strategies to meet WHO pre-qualifications and new GMP
- Highlight advances and collaborations in China’s high-growth market
- DETAILED analysis on existing and upcoming opportunities in China and beyond
- Co-located with the 7th annual China Pharmaceutical R&D Summit and 3 rd annual Biosimilars Asia conference to maximize cross-learning, partnering and networking opportunities
|
|
| |
|
|
AGENDA AT A GLANCE |
 |
| |
|
AM |
LUNCH |
PM |
MON
23 APRIL |
Pre-Conference Workshops:
US Market Entry: A Regulatory, Legal, and Medical Communication Perspective (Full Day)
Expression Systems for Antibody and Vaccine Biomanufacturing (Full Day) |
LUNCH,
AM & PM BREAKS |
US Market Entry: A Regulatory, Legal, and Medical Communication Perspective
Expression Systems for Antibody and Vaccine Biomanufacturing
Meet the Speakers Reception (by Invitation only) |
TUE
24 APRIL |
China Pharma R&D, Vaccines & Biosimilars
JOINT PLENARY SESSION
Global and Regional Keynote Presentations
On Pharma R&D |
EXHIBITION & POSTER SESSION
DISCUSSION DEN
CRO Clinic / Onsite “Lab’ & Demonstrations
China Technology & Services Pavilion |
China Pharmaceutical R&D Summit
• Regulatory Snapshots
• R&D Leaders Panel
• Investment & Funding
• ‘Pharma Idol’: Innovation
Showcase
• CXO Panel Discussion
• Funding for Innovation |
Discussion Den:
In depth roundtable discussions on Regulatory and
Collaborations in Key Asian Countries
NETWORKING RECEPTION
EVENING DINNER (Optional) |
Vaccines China
• Market Trends & Outlook
• Vaccines Quality Control &
Compliance
• Novel Development of Vaccines
• Regulatory Snapshots
• Visionary Panel Discussion |
Biosimilars Asia
• Market Entry & Opportunities
• Commercial Viability
• Regulatory Snapshots
• Visionary Panel Discussion |
|
WED 25 APRIL |
China Pharmaceutical R&D Summit
• Drug Development & Partnering Strategies
• Emerging Business Models< in R&D
• Discovery & Early Stage Devt
• Role of Academia in Drug
Discovery & Development |
Vaccines China
• Novel Vaccine Candidates for Tropical Diseases
• Research and Clinical Updates for EV71 vaccines |
Biosimilars Asia
• External Collaborations & Commercial Value
• Breaking into Protectionist Markets
• Intellectual Property Legal Debate |
|
China Pharmaceutical R&D
Summit
• ‘Pharma Idol’: Innovation Showcase and Awarding
• Clinical Development & Partnerships in Asia
• Future Opportunities in Biosimilars & Biobetters
• Closing Visionary Panel Discussion |
Vaccines China
• Innovations & Technological Advancements
• Future Opportunities for Sustainable Return on Investment |
Biosimilars Asia
• Mad about mAbs
• Developing Biosimilars & Biobetters
• Winning Buy-in
• Closing Panel Debate |
|
THU 26 APRIL |
Post-Conference Workshops:
Next Generation of Vaccine Facilities
with Focus on Design & Containment
Turning Strategies into Tactical
Plans to Optimize Market Entry –
Balancing Commercial, Regulatory
and Investments to Deliver Successful
Business Models |
|
|
.jpg)
